Sign In
Buy LXRX
$2.15
+0.140 (+6.97%)
At Close: Jun 22, 2026
Here's Why You Should Add LXRX Stock to Your Portfolio Now
11:41am, Monday, 22'nd Jun 2026
Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
09:45am, Thursday, 11'th Jun 2026
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
08:00am, Wednesday, 03'rd Jun 2026
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups Presentations highlight consistent A1c reductio
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
08:30am, Thursday, 28'th May 2026
THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies G
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
08:30am, Tuesday, 12'th May 2026
THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C.
Lexicon Pharmaceuticals Q1 Earnings Call Highlights
04:12pm, Friday, 08'th May 2026
Lexicon Pharmaceuticals NASDAQ: LXRX executives highlighted progress across late-stage regulatory programs and efforts to bolster the company's financial position during the company's first-quarter 20
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
05:11pm, Thursday, 07'th May 2026
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1
09:55am, Thursday, 07'th May 2026
Lexicon Pharmaceuticals (LXRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
07:30am, Thursday, 07'th May 2026
SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA ® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
04:05pm, Monday, 04'th May 2026
THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC) th
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
08:00am, Thursday, 30'th Apr 2026
THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
08:00am, Friday, 17'th Apr 2026
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving Average – Here’s Why
02:11am, Tuesday, 31'st Mar 2026
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $1.39 and traded as h
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
11:35am, Tuesday, 24'th Mar 2026
Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
08:00am, Tuesday, 24'th Mar 2026
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action Additional analys
